Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: J Clin Psychopharmacol. 2017 Aug;37(4):394–400. doi: 10.1097/JCP.0000000000000720

Table 3. Mean Z-Scores for Composite Cognitive Primary Outcome* by Treatment Group and Week.

Galantamine Oxytocin Placebo
Week N Mean S.D. N Mean S.D. N Mean S.D.
0 15 -0.22 0.47 14 0.23 0.92 16 0.21 0.83
6 15 -0.05 0.68 14 0.33 1.00 15 0.18 0.69
Change 15 0.17 0.44 14 0.10 0.37 15 0.03 0.41
*

Composite Cognitive Primary Outcome = mean of z-scores from BACS Symbol Digit T-score, HVLT T-score, and Rapid Visual Information Processing (RVIP) test z-score.

ANCOVA estimate of treatment differences on z-scores at Week 6, adjusted for baseline values of the corresponding z-score:
  • Galantamine versus placebo: 0.11 ± 0.15; t= 0.71, df=40, p=0.48
  • Oxytocin versus placebo: 0.08 ± 0.15 ; t= 0.50, df=40, p=0.62